)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Plus Therapeutics
Plus Therapeutics (PSTV) investor relations material
Plus Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Achieved significant business progress in 2025, focusing on CNSide commercial scale-up and REYOBIQ pivotal trial readiness.
Completed a $15 million upsized public offering, extending cash runway and supporting commercialization and clinical programs.
Expanded CNSide laboratory licensing to 49 states, reaching 95% of the U.S. population.
Secured national coverage agreements for CNSide with Humana and UnitedHealthcare, covering 67 million people.
Financial highlights
Cash and investments at year-end 2025 totaled $13.1 million, up from $3.6 million at year-end 2024.
Recognized $5.2 million in grant revenue in 2025, compared to $5.8 million in 2024.
Operating loss for 2025 was $15.3 million, compared to $14.7 million in 2024, mainly due to CNSide team expansion.
Net loss for 2025 was $22.4 million ($0.29 per share), versus $13.0 million ($1.95 per share) in 2024, primarily due to changes in fair value of derivative instruments.
Outlook and guidance
Plans to define optimal dose/interval for REYOBIQ in RESPECT-LM Phase 2 trial, with data expected in Q3 2026.
Aims to complete enrollment in RESPECT-GBM Phase 2 trial and align with FDA on pivotal trial design, with data expected in Q4 2026.
Expects increased R&D and G&A expenditures in 2026 due to clinical trial costs, manufacturing scale-up, and CNSide team expansion.
Targets CNSide commercial payer coverage to exceed 150 million lives and achieve over 1,250 annualized test orders.
Goal for CNSide Diagnostics to reach breakeven by 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Plus Therapeutics
- Positive clinical data, new grants, and CNSide launch offset by financial and regulatory risks.PSTV
Q2 20241 Feb 2026 - $15M raise funds clinical trials, CNSide growth, and 2026 expansion with strong payor coverage.PSTVBusiness update22 Jan 2026
- Promising CNS radiotherapeutic programs advance toward pivotal trials and commercial diagnostics.PSTVH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Clinical progress and new financing support growth, but liquidity and compliance risks remain.PSTVQ3 202414 Jan 2026
- IPO seeks to fund CNS cancer radiotherapeutics and diagnostics amid ongoing financial risk.PSTVRegistration Filing9 Jan 2026
- $15M raised, CNSide launch in 2025, and improved net loss per share for 2024.PSTVQ4 202426 Dec 2025
- Over 1.5B shares registered for resale; proceeds from warrant exercises may fund oncology innovation.PSTVRegistration Filing16 Dec 2025
- Plans to raise up to $100M for radiotherapeutics, with high risk and a focus on CNS cancers.PSTVRegistration Filing16 Dec 2025
- Extreme dilution risk from large resale registration; focus on CNS cancer radiotherapeutics.PSTVRegistration Filing16 Dec 2025
Next Plus Therapeutics earnings date
Q1 202630 Apr, 2026
Plus Therapeutics
Next Plus Therapeutics earnings date
Q1 202630 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative therapies for rare cancers. The company leverages nanotechnology and targeted drug delivery platforms to design precision treatments, including radiotherapeutics for central nervous system cancers and other challenging oncological conditions. The company is headquartered in Austin, Texas, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage